Definitive Contract 75A50124C00059

This is a $293,443,870.00 definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The contract is for the provision of therapeutic interventions and medical countermeasures against infectious diseases and biothreats, including viral hemorrhagic fevers like Ebola, Marburg, and Lassa, as well as botulinum neurotoxin. Mapp...

This is a $856,704,795.58 definitive cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in infectious disease treatments. The contract is for the procurement of therapeutics to address Ebola, Sudan, and Marburg viruses. There is no set-aside designation for this contract, which has an ultimate completion date of...

This is a $62,511,942.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California. The contract is for the development of an anti-Sudan ebolavirus medical countermeasure, a critical public health and national security priority. Mapp Biopharmaceutical has a strong...

This is a cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The contract, which has a potential value of $7,486,450.79, is for an expanded access protocol for the drug ZMapp to treat viral hemorrhagic fevers like Ebola, Marburg, and Lassa. Mapp Biopharmaceutical is a prime contractor for ASPR, having...

This federal contract award from the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the Department of Health and Human Services (HHS), is for the procurement of Ebola virus antibody and diagnostic tests to detect the virus in cadavers. The $2,222,900.00 firm fixed-price purchase order was awarded to OraSure Technologies Inc., a for-profit manufacturer of medical diagnostic products, on June 22, 2022. The contract has an ultimate completion date...

This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Ridgeback Biotherapeutics LP, a for-profit, woman-owned business. The contract, valued at $13,988,547.00, is for Ridgeback Biotherapeutics' efforts related to the development of the monoclonal antibody (MAB) treatment MAB114 for Ebola. The contract does not have a set-aside designation and is a cost-no-fee arrangement. The period of...

This is a sole-source contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Ridgeback Biotherapeutics LP for the development and manufacturing of the monoclonal antibody treatment mAb114 for Ebola virus disease (EVD). The contract has a ceiling value of $159,990,035.88 and a period of performance through July 31, 2023. It was awarded on March 19, 2020 as a cost-plus-fixed-fee definitive contract. The...

This is a federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency within the U.S. Department of Health and Human Services, to Profectus Biosciences, Inc., a small business contractor. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a ceiling value of $7,524,330.27 and a period of performance through November 30, 2016. The contract is for the GMP (Good Manufacturing Practice) manufacture of the...

This $2,306,148 federal contract was awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Battelle Memorial Institute to support an efficacy study of a monoclonal antibody (MAb) therapeutic against the Ebola virus (EBOV) lethal challenge in rhesus macaques. The contract is a Delivery Order issued under Battelle's BARDA Biological Animal Model Development 2017-2022 Indefinite Delivery/Indefinite Quantity (IDIQ)...

<p>This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Boston Bioscience Inc. on September 27, 2012. The contract, valued at $35,705.00, is for the delivery of EBOLA GP (Z) CARBOXYL TERMINUS ACID PEPTIDES, 15 AMINO ACIDS IN LENGTH. The contract has a completion date of October 3, 2012 and does not utilize a set-aside designation.</p>